Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and clinical features of the RA and control patients admitted to participating Victorian hospitals with acute MI between 1995 and 2005

From: Rheumatoid arthritis patients receive less frequent acute reperfusion and secondary prevention therapy after myocardial infarction compared with the general population

  RA (n= 90) Controls (n= 90)
Female, n (%) 55 (61) 55 (61)
Age in years, mean (SD) 71 (10) 71 (10)
RA disease duration in years, mean (SD) 20 (13) -
Seropositive, n (%)a 35 (78) -
No. of DMARDs, mean (SD) 1.4 (1.1) -
Taking NSAID at time of MI, n (%) 21 (23) 6 (7)b
Preexisting comorbidities:   
   Ischemic heart disease, n (%) 31 (34) 33 (37)
   Prior MI, n (%) 10 (11) 11 (12)
   Cerebrovascular disease, n (%) 8 (9) 9 (10)
   Peripheral vascular disease, n (%) 19 (21) 5 (6)b
   IDDM, n (%) 3 (3) 1 (1)
   NIDDM, n (%) 22 (24) 27 (30)
   Hypertension, n (%) 52 (58) 56 (62)
   Hypercholesterolemia, n (%) 22 (24) 38 (42)b
   Current smoker, n (%) 14 (15) 16 (18)
   Previous smoker, n (%) 41 (46) 27 (30)
   Congestive cardiac failure, n (%) 15 (17) 11 (12)
   Chronic lung disease, n (%) 28 (31) 16 (18)
   Chronic renal impairment, n (%) 15 (17) 8 (9)
  1. Chronic lung disease: asthma, chronic obstructive airways disease, and pulmonary fibrosis; DMARD, disease-modifying antirheumatic drug; IDDM, insulin-dependent diabetes mellitus; MI, myocardial infarction; NIDDM, non-insulin-dependent diabetes mellitus; NSAID, nonsteroidal antiinflammatory drug; RA, rheumatoid arthritis. aData available for 45 of 90 RA patients. bP value < 0.05.